

1002P: Compared with the difference in efficacy between EGFR-TKIs alone and EGFR-TKIs combined with craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastasis. A propensity-score matched analysis

In *EGFR*-mutant lung adenocarcinoma patients with BM, targeted therapy combined with craniocerebral radiotherapy is an optimal treatment.




Fig.1

Fig. 1 (a) Comparison of iPFS between the EGFR-TKIs combined with cerebral radiotherapy group and EGFR-TKI alone group before PSM. (A) Comparison of iPFS between the EGFR-TKIs combined with cerebral radiotherapy group and EGFR-TKI alone group after PSM;




Fig.2

Fig. 2 (a) Comparison of PFS between the EGFR-TKIs combined with cerebral radiotherapy group and EGFR-TKI alone group before PSM. (A) Comparison of PFS between the EGFR-TKIs combined with cerebral radiotherapy group and EGFR-TKI alone group after PSM.

| Characteristics ^{1,2} | Before propensity score matching ^{3,4} | | After propensity score matching ^{3,4} | |
|--------------------------------------|---|---|--|---|
| | EGFR-TKIs combined with cerebral radiotherapy group ^{4,5} (n=230) ^{1,2} | EGFR-TKI alone group ^{4,5} (n=61) ^{1,2} | EGFR-TKIs combined with cerebral radiotherapy group ^{4,5} (n=51) ^{1,2} | EGFR-TKI alone group ^{4,5} (n=51) ^{1,2} |
| Age, years ^{1,2} | 54(23.81) ^{1,2} | 57(23.81) ^{1,2} | 57(23.81) ^{1,2} | 56(23.77) ^{1,2} |
| >60 ^{1,2} | 66(28.7) ^{1,2} | 28(45.9) ^{1,2} | 17(33.3) ^{1,2} | 22(43.1) ^{1,2} |
| ≤60 ^{1,2} | 164(71.3) ^{1,2} | 33(54.1) ^{1,2} | 34(66.7) ^{1,2} | 29(56.9) ^{1,2} |
| Sex ^{1,2} | | | | |
| Female ^{1,2} | 148(64.3) ^{1,2} | 35(57.4) ^{1,2} | 27(52.9) ^{1,2} | 30(58.8) ^{1,2} |
| male ^{1,2} | 82(35.7) ^{1,2} | 26(42.6) ^{1,2} | 24(47.1) ^{1,2} | 21(41.2) ^{1,2} |
| Smoking Status ^{1,2} | | | | |
| Never ^{1,2} | 179(77.8) ^{1,2} | 46(75.4) ^{1,2} | 38(74.5) ^{1,2} | 39(76.5) ^{1,2} |
| Former/current ^{1,2} | 51(22.2) ^{1,2} | 15(24.6) ^{1,2} | 13(25.5) ^{1,2} | 12(23.5) ^{1,2} |
| EGFR Mutation ^{1,2} | | | | |
| Exon 18 ^{1,2} | 5(2.2) ^{1,2} | 1(1.6) ^{1,2} | 0(0) ^{1,2} | 0 ^{1,2} |
| Exon 19 ^{1,2} | 94(40.9) ^{1,2} | 28(45.9) ^{1,2} | 23(45.1) ^{1,2} | 23(45.1) ^{1,2} |
| Exon 21 ^{1,2} | 113(49.1) ^{1,2} | 30(49.2) ^{1,2} | 24(47.1) ^{1,2} | 25(49.0) ^{1,2} |
| Unclear ^{1,2} | 18(7.81) ^{1,2} | 2(3.3) ^{1,2} | 4(7.8) ^{1,2} | 3(5.9) ^{1,2} |
| Systemic Therapy ^{1,2} | | | | |
| First-line EGFR TKIs ^{1,2} | 114(49.6) ^{1,2} | 44(72.1) ^{1,2} | 29(56.9) ^{1,2} | 36(70.6) ^{1,2} |
| Second-line EGFR TKIs ^{1,2} | 116(50.4) ^{1,2} | 17(27.9) ^{1,2} | 22(43.1) ^{1,2} | 15(29.4) ^{1,2} |
| Lung molGPA ^{1,2} | | | | |
| 1-2 ^{1,2} | 106(46.1) ^{1,2} | 18(29.5) ^{1,2} | 12(23.5) ^{1,2} | 13(25.5) ^{1,2} |
| 2.5-3 ^{1,2} | 92(40.0) ^{1,2} | 36(59.0) ^{1,2} | 32(62.8) ^{1,2} | 32(62.7) ^{1,2} |
| 3.5-4 ^{1,2} | 32(13.9) ^{1,2} | 7(11.5) ^{1,2} | 7(13.7) ^{1,2} | 6(11.8) ^{1,2} |

Abbreviation: EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitors^{4,5}

Conflicts of interest statement

All authors have no conflict of interest with any company or organization.

References Disclosures

None.